Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 263

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1B
Chunk 263
---
 in the United States.

Research and development expenses 

Research and development expenses increased $97.2 million, from $130.5 million for the year ended December 31, 2023 to $227.7 million for the year ended December 31, 2024. Third-party expenses increased by $18.1 million due primarily to an increase in clinical trial and manufacturing activities, personnel related expenses increased by $6.6 million driven by headcount growth, and other research and development costs increased by $0.5 million. Additionally, license agreement payments increased by $72.0 million due to the payment of the MabCare license agreement upfront payment, accrual of the MabCare license agreement milestone payment, and payment of the Viracta license agreement amendment payment during the year ended December 31, 2024. 

119

The following table summarizes our external and internal research and development expenses for the years ended December 31, 2024 and 2023:

    Year EndedDecember 31,

    2024

    2023

    (in thousands)

    External costs:

    Third-party CRO, CMO and other third-party clinical trial costs (1)
     
    $
    89,400

    $
    71,294

    MabCare license agreement upfront payment

    55,000

    —

    MabCare license agreement milestone payment

    20,000

    —

    Viracta license agreement payment

    5,000

    5,000

    Sprint license agreement upfront payment

    —

    3,000

    Other research and development costs

    8,949

    8,465

    Internal costs:

    Employee related expenses

    49,353

    42,762

    Total research and development expenses
     
    $
    227,702

    $
    130,521

(1)Third-party CRO, CMO and other clinical trial costs for the tovorafenib, pimasertib, DAY301, and VRK1 programs were $74.8 million, $3.8 million, $4.2 million, and $6.6 million, respectively, for the year ended December 31, 2024 compared to $65.5 million, $4.0 million, $0, and $1.8 million, respectively, for the year ended December 31, 2023.

Selling, general